GSM and Vaginal Estrogen: The Treatment Most Women Are Never Offered


In my years of practice, few conversations have changed women's daily lives as quickly as this one. A patient comes in for something else entirely. Near the end of the visit, almost as an afterthought, she mentions that sex has become painful, or that she has had three urinary tract infections this year, or that she feels dry and irritated all the time. Then she adds, "But I assume that's just part of getting older."

It is part of menopause. It does not have to be part of her life.

The condition is called genitourinary syndrome of menopause, or GSM. It is one of the most common consequences of estrogen loss, one of the most treatable, and one of the least discussed. Here is what every woman deserves to know.


The Menopause Society estimates that GSM affects between 27% and 84% of postmenopausal women.


Why GSM Is So Often Missed

The Menopause Society estimates that GSM affects between 27% and 84% of postmenopausal women. The range is wide because so many women never report their symptoms, and so many clinicians never ask. In its 2020 position statement, the Society described GSM as underdiagnosed and undertreated, and it recommended that every perimenopausal and postmenopausal woman be educated about and screened for it.

Three things make GSM easy to overlook:

  • It develops slowly. Changes accumulate over months and years, so women adjust without noticing how much has shifted.

  • It feels private. Many women are embarrassed to bring up vaginal, sexual, or bladder symptoms, especially with a provider they see only briefly.

  • It does not go away on its own. Hot flashes often fade with time. GSM tends to do the opposite. Because the tissue changes are driven by ongoing estrogen deficiency, symptoms usually progress without treatment.

The term itself is fairly new. Experts adopted "genitourinary syndrome of menopause" in 2014 to replace older language that was inaccurate and frankly demeaning, and to make clear that this condition affects the bladder and urethra, not only the vagina.

What Estrogen Does in These Tissues

The tissues of the vulva, vagina, urethra, and bladder are rich in estrogen receptors. When estrogen is present, it keeps the lining of the vagina thick and layered, supports blood flow and natural lubrication, and maintains the elastic collagen that allows the tissue to stretch comfortably.

Estrogen also protects you in a less obvious way. It helps the vaginal lining store glycogen, a sugar that feeds protective Lactobacillus bacteria. These bacteria produce lactic acid, keeping the vaginal environment acidic. That acidity makes it hard for harmful bacteria, including the E. coli that cause most urinary tract infections, to take hold.

When estrogen falls, that whole system shifts. The lining thins and becomes fragile. Lubrication decreases. Lactobacilli decline, vaginal pH rises, and the area becomes more welcoming to bacteria that can travel to the bladder. That is the biological reason so many women develop recurrent UTIs after menopause.

How GSM Shows Up

GSM can affect three areas of your life, and you may notice symptoms in one, two, or all three.

Everyday comfort

  • Dryness, burning, or itching, even when you are not sexually active

  • Irritation from clothing, exercise, or sitting for long periods

  • Light bleeding or discomfort during a pelvic exam

Intimacy

  • Pain with penetration or afterward

  • Less natural lubrication and less arousal

  • Small tears or spotting after sex

Bladder health

  • Urgency, or needing to urinate more often

  • Burning with urination when no infection is found

  • Recurrent urinary tract infections

You do not need every symptom to have GSM, and it affects women whether or not they are sexually active.

The Treatment Options

The Menopause Society's guidance follows a sensible step-by-step approach.

For mild symptoms, non-hormonal options are a reasonable starting point. A long-acting vaginal moisturizer, used regularly a few times a week, can improve day-to-day comfort. A good-quality lubricant can make intimacy more comfortable. These products help, but they do not reverse the underlying tissue changes.

For moderate to severe symptoms, or when moisturizers are not enough, several prescription options are effective:

  • Low-dose vaginal estrogen, available as a cream, a small vaginal tablet or softgel insert, or a flexible ring that releases estrogen steadily for about three months. These are the most widely studied treatments for GSM.

  • Vaginal DHEA (prasterone), a nightly insert. DHEA is converted into estrogen and androgens within the vaginal tissue itself.

  • Ospemifene, an oral medication that acts like estrogen on vaginal tissue. It can be an option for women who prefer not to use a vaginal product.

  • Systemic hormone therapy, such as a patch, gel, or pill, when a woman also has hot flashes or night sweats. Some women on systemic therapy still need vaginal estrogen as well to fully control GSM.

Most women notice improvement within a few weeks, with fuller benefit over about two to three months. GSM is a chronic condition, so treatment is generally ongoing. If you stop, symptoms typically return.

Pelvic floor physical therapy can be a valuable addition, especially if pain with intimacy has led to protective tightening of the pelvic muscles.

Is Vaginal Estrogen Safe?

This is the question that keeps many women from starting treatment, so I want to answer it carefully.

Low-dose vaginal estrogen works locally. Blood estrogen levels in women using it generally remain within the normal postmenopausal range. According to The Menopause Society, women using low-dose vaginal estrogen do not need to add a progestogen to protect the uterus, and routine endometrial monitoring is not recommended for women without symptoms. Any vaginal bleeding should always be evaluated.

For decades, however, vaginal estrogen carried the same boxed warning as systemic hormone therapy, listing risks such as stroke, heart disease, breast cancer, and dementia. Those warnings were based on studies of systemic hormones, not low-dose vaginal products. On November 10, 2025, the FDA announced it would remove the cardiovascular, breast cancer, and dementia language from the boxed warnings on menopausal hormone therapy, and that vaginal estrogen labels would focus on the risks relevant to local use. Updated labels began receiving approval in February 2026. The American College of Obstetricians and Gynecologists and the American Urological Association had long advocated for this change.

What about breast cancer survivors? This deserves an individualized discussion with your oncologist. The evidence has become more reassuring. A 2024 study in JAMA Oncology of nearly 50,000 women with breast cancer found no increase in breast cancer deaths among those who used vaginal estrogen. A 2024 Danish nationwide study in BMJ Medicine found that vaginal estradiol tablets were not associated with a higher rate of developing breast cancer. Caution is still advised for women taking aromatase inhibitors, and vaginal DHEA or non-hormonal options may be considered. If you have been told "no hormones, ever," it is worth asking whether that answer was about systemic therapy or local therapy, because they are not the same.

The UTI Connection

If you are a peri- or postmenopausal woman with recurrent UTIs, vaginal estrogen is not just an option. It is guideline-recommended care. The American Urological Association, the Canadian Urological Association, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction advise that clinicians recommend vaginal estrogen to reduce the risk of future infections, as long as there is no contraindication. That recommendation was reaffirmed in the 2025 update of their guideline.

Antibiotics treat each infection. Restoring the health of the tissue addresses why the infections keep returning, and it may reduce your exposure to repeated antibiotic courses.

How to Start the Conversation

Bring it up at the beginning of your appointment, not at the end. Use the name: "I think I may have genitourinary syndrome of menopause." Then come prepared with a few questions:

  • Which of my symptoms could be caused by GSM?

  • Am I a candidate for low-dose vaginal estrogen, and which form would suit me?

  • If estrogen is not right for me, what are the alternatives?

  • If I have a history of breast cancer, can we coordinate with my oncologist?

  • How long until I should expect improvement, and when should I follow up?

If your provider is not comfortable with this conversation, you can find a menopause-trained clinician through The Menopause Society, or see a urogynecologist, a specialist in pelvic floor and bladder health.

You Do Not Have to Adapt to This

GSM is not a vanity concern or a minor inconvenience. It affects comfort, intimacy, bladder health, sleep, and confidence, and it is as much a part of menopause care as bone density and heart health. With treatment, the tissue can become healthier, more comfortable, and more resilient. You deserve to feel at home in your own body, at every age.


Defy Menopause - Own the Change

Many women tell me: "One day I feel amazing. The next, I can barely get out of bed. Is this normal?"

Yes, it is. And no, you don’t have to suffer through it alone.

Hormonal fluctuations during perimenopause can make you feel like you’ve lost control of your body. But knowledge is powerful. And there are clear, science-backed ways to support your hormones, ease symptoms, and reclaim your energy.

That’s exactly why I created Defy Menopause: Own the Change — a 30-day program designed to give you the tools, knowledge, and support you need to move through these changes with clarity and confidence.

Inside, you’ll find:

  • Access to Dr. Tracy Verrico at one (1) live, group session

  • Clear action steps for managing symptoms naturally

Because you deserve more than just "putting up with it."

You deserve to thrive.



Medical Disclaimer: The information provided in this blog is for general educational and informational purposes only and is not intended as, nor should it be considered, medical advice. This content does not establish a physician-patient relationship and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this newsletter. If you think you may have a medical emergency, call your doctor or emergency services immediately.


References

  1. The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609

  2. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063-1068.

  3. Ackerman AL, Bradley M, D'Anci KE, et al. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). Journal of Urology. 2025. doi:10.1097/JU.0000000000004723

  4. McVicker L, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncology. 2024;10(1):103-108. doi:10.1001/jamaoncol.2023.4508

  5. Meaidi A, Pourhadi N, Lokkegaard EC, Torp-Pedersen C, Morch LS. Association of vaginal oestradiol and the rate of breast cancer in Denmark: registry based, case-control study, nested in a nationwide cohort. BMJ Medicine. 2024;3(1):e000753. doi:10.1136/bmjmed-2023-000753

  6. U.S. Food and Drug Administration. HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. News release, November 10, 2025.

  7. American College of Obstetricians and Gynecologists. Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstetrics & Gynecology. 2016;127(3):e93-e96.


Dr. Tracy Verrico

Hi, I’m Dr. Tracy Verrico, board-certified OB-GYN, hormonal health expert, wealth educator, and speaker. I empower women to live their healthiest and wealthiest life.

https://www.drtracyverrico.com/
Previous
Previous

Budget First, List Second: How to Set Holiday Money Boundaries Without the Guilt

Next
Next

The Hidden Cost of Keeping Up With Friends: How Your Social Life Shapes Your Finances